GSK and US-based Vir Biotechnology will evaluate a second antibody-based treatment in patients with mild to moderate COVID-19 in an early- to mid-stage trial, the companies said on Tuesday.The new trial, supported by England's National Health Service, is expected to begin in the first quarter of 2021 at multiple sites across the UK, the companies said in a joint statement.Preclinical data suggested the companies' monoclonal antibody (mAb) has the ability to clear infected cells and the potential to enhance virus-specific T cell function, which could help treat and/or prevent infection.This would become the second mAb from the Vir-GSK collaboration to be investigated as a potential COVID-19 treatment, with the first currently being assessed.